Anti-TNF11/ ODF/ TNFSF11 monoclonal antibody

Anti-TNF11/ ODF/ TNFSF11 antibody for FACS & in-vivo assay

Target products collectionGo to ODF/TNFSF11 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T21334-Ab-1/ GM-Tg-hg-T21334-Ab-2Anti-Human ODF/TNFSF11 monoclonal antibodyHuman
GM-Tg-rg-T21334-Ab-1/ GM-Tg-rg-T21334-Ab-2Anti-Rat ODF/TNFSF11 monoclonal antibodyRat
GM-Tg-mg-T21334-Ab-1/ GM-Tg-mg-T21334-Ab-2Anti-Mouse ODF/TNFSF11 monoclonal antibodyMouse
GM-Tg-cynog-T21334-Ab-1/ GM-Tg-cynog-T21334-Ab-2Anti-Cynomolgus/ Rhesus macaque ODF/TNFSF11 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T21334-Ab-1/ GM-Tg-felg-T21334-Ab-2Anti-Feline ODF/TNFSF11 monoclonal antibodyFeline
GM-Tg-cang-T21334-Ab-1/ GM-Tg-cang-T21334-Ab-2Anti-Canine ODF/TNFSF11 monoclonal antibodyCanine
GM-Tg-bovg-T21334-Ab-1/ GM-Tg-bovg-T21334-Ab-2Anti-Bovine ODF/TNFSF11 monoclonal antibodyBovine
GM-Tg-equg-T21334-Ab-1/ GM-Tg-equg-T21334-Ab-2Anti-Equine ODF/TNFSF11 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T21334-Ab-1/ GM-Tg-hg-T21334-Ab-2; GM-Tg-rg-T21334-Ab-1/ GM-Tg-rg-T21334-Ab-2;
GM-Tg-mg-T21334-Ab-1/ GM-Tg-mg-T21334-Ab-2; GM-Tg-cynog-T21334-Ab-1/ GM-Tg-cynog-T21334-Ab-2;
GM-Tg-felg-T21334-Ab-1/ GM-Tg-felg-T21334-Ab-2; GM-Tg-cang-T21334-Ab-1/ GM-Tg-cang-T21334-Ab-2;
GM-Tg-bovg-T21334-Ab-1/ GM-Tg-bovg-T21334-Ab-2; GM-Tg-equg-T21334-Ab-1/ GM-Tg-equg-T21334-Ab-2
Products NameAnti-ODF/TNFSF11 monoclonal antibody
Formatmab
Target NameODF
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-ODF benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-ab-140Pre-Made Denosumab biosimilar, Whole mAb, Anti-TNFSF11/ODF Antibody: Anti-OPGL/sCD254/OPTB2/RANKL/TNLG6B/TRANCE/hRANKL2 therapeutic antibody
    Target AntigenProducts DevelopingMulti-species TNF11/ ODF/ TNFSF11 VLP (virus-like particle) (Products Developing)
    CytokineGM-Tg-g-T21334-Ag-1tumor necrosis factor (ligand) superfamily, member 11 (TNFSF11) protein
    ORF Viral VectorvGMLP001907human TNFSF11 Lentivirus particle
    ORF Viral VectorpGMLP001907human TNFSF11 Lentivirus plasmid
    ORF Viral VectorpGMAAV000113mouse Tnfsf11 AAV plasmid
    ORF Viral VectorvGMAAV000113mouse Tnfsf11 AAV particle


    Target information

    Target IDGM-T21334
    Target NameODF
    Gene ID8600,21943,117516,699955,609418,724036,513836,100060254
    Gene Symbol and SynonymsCD254,hRANKL2,Ly109l,ODF,OPGL,OPTB2,RANKL,sOdf,TNFSF11,TNLG6B,TRANCE
    Uniprot AccessionO14788,Q9ESE2
    Uniprot Entry NameTNF11_HUMAN,TNF11_RAT
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index, Cytokine Target
    DiseaseCancer
    Gene EnsemblENSG00000120659
    Target ClassificationCheckpoint-Immuno Oncology, Tumor-associated antigen (TAA)

    The target: ODF, gene name: TNFSF11, also named as CD254, ODF, OPGL, OPTB2, RANKL, TNLG6B, TRANCE, hRANKL2, sOdf. This gene encodes a member of the tumor necrosis factor (TNF) cytokine family which is a ligand for osteoprotegerin and functions as a key factor for osteoclast differentiation and activation. This protein was shown to be a dentritic cell survival factor and is involved in the regulation of T cell-dependent immune response. T cell activation was reported to induce expression of this gene and lead to an increase of osteoclastogenesis and bone loss. This protein was shown to activate antiapoptotic kinase AKT/PKB through a signaling complex involving SRC kinase and tumor necrosis factor receptor-associated factor (TRAF) 6, which indicated this protein may have a role in the regulation of cell apoptosis. Targeted disruption of the related gene in mice led to severe osteopetrosis and a lack of osteoclasts. The deficient mice exhibited defects in early differentiation of T and B lymphocytes, and failed to form lobulo-alveolar mammary structures during pregnancy. Two alternatively spliced transcript variants have been found. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.